Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;22(8):1117-1118.
doi: 10.1016/S1473-3099(22)00422-4. Epub 2022 Jun 28.

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Prerna Arora  1 , Amy Kempf  1 , Inga Nehlmeier  1 , Sebastian R Schulz  2 , Anne Cossmann  3 , Metodi V Stankov  4 , Hans-Martin Jäck  2 , Georg M N Behrens  4 , Stefan Pöhlmann  1 , Markus Hoffmann  5
Affiliations
Comment

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5

Prerna Arora et al. Lancet Infect Dis. 2022 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AK, IN, SP, and MH conduct contract research (ie, testing of vaccinee sera for neutralising activity against SARS-CoV-2) for an industrial entity, unrelated to this Correspondence. GMNB served as an adviser for Moderna, unrelated to this Correspondence. All other authors declare no competing interests. SP acknowledges funding by Bundesministerium für Bildung und Forschung (01KI2006D, 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14–76103–184, MWK HZI COVID-19), and the German Research Foundation (PO 716/11–1, PO 716/14–1). H-MJ received funding from BMBF (01KI2043, NaFoUniMedCovid19-COVIM: 01KX2021), Bavarian State Ministry for Science and the Arts, and Deutsche Forschungsgemeinschaft through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding by German Center for Infection Research (grant no 80018019238) and a European Regional Development Fund (Defeat Corona, ZW7–8515131).

Comment on

  • Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
    Yamasoba D, Kosugi Y, Kimura I, Fujita S, Uriu K, Ito J, Sato K; Genotype to Phenotype Japan (G2P-Japan) Consortium. Yamasoba D, et al. Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9. Lancet Infect Dis. 2022. PMID: 35690075 Free PMC article. No abstract available.
  • BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. Cao Y, et al. Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17. Nature. 2022. PMID: 35714668 Free PMC article.

References

    1. Hoffmann M, Krüger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447–456. e11. - PMC - PubMed
    1. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217 - PMC - PubMed
    1. Cameroni E, Bowden JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature. 2022;602:664–670. - PMC - PubMed
    1. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection (version 2) bioRxiv. 2022 doi: 10.1101/2022.04.30.489997. published online June 14. (preprint). - DOI - PMC - PubMed
    1. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed